A61K 40/4253
Gtpases
Official title: {GTPases, e.g. Ras or Rho}
A61K40/4253 (Gtpases) appears on 31 US grants and 96 published applications in this corpus.
Search patents in A61K- Granted patents
- 31
- Published applications
- 96
- Assignees
- 61
- Inventors
- 210
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 4 |
| 2020 | 0 | 8 |
| 2021 | 3 | 6 |
| 2022 | 6 | 12 |
| 2023 | 2 | 16 |
| 2024 | 3 | 15 |
| 2025 | 3 | 13 |
| 2026 | 8 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Genetically engineered phagocytes, and related compositions, vectors, methods and systems22 Sep 2026US 12,741,025 B2The Regents of the University of California
- Nant cancer vaccine16 Jun 2026US 12,653,874 B2ImmunityBio, Inc.
- HLA class II-restricted DRB T cell receptors against RAS with G12D mutation16 Jun 2026US 12,655,193 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- HLA class II-restricted DRB T cell receptors against RAS with G12V mutation16 Jun 2026US 12,655,194 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- HLA class II-restricted DQ T cell receptors against RAS with G13D mutation16 Jun 2026US 12,655,195 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Hla class ii-restricted drb t cell receptors against ras with g12d mutation10 Sep 2026US 2026/0265338 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Tcr molecule targeting kras g12v mutation, cell, and uses thereof27 Aug 2026US 2026/0250388 A1Beijing Dcty Biotech Co., Ltd.
- Multiepitope vaccine cassettes30 Jul 2026US 2026/0216307 A1Seattle Project Corp.
- T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*03:01 in lung cancer30 Jul 2026US 2026/0216333 A1Board of Regents, The University of Texas System
- Bltp3a-silenced antigen-specific engineered t cells16 Jul 2026US 2026/0199466 A1Rutgers, The State University of New Jersey
Most cited
By later US patents
- Immune reactivity to expressed activated oncogenes for diagnosis of malignancy20US 5,320,947 AWashington Research Foundation · 1994
- Immune reactivity to expressed activated oncogenes for diagnosis and treatment of malignancy13US 5,601,989 AWashington Research Foundation · 1997
- Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes12US 7,709,002 B1The United States of America as represented by the Department of Health and Human Services · 2010
- Immune reactivity to expressed activated oncogenes for diagnosis and treatment of malignancy7US 5,773,230 AWashington Research Foundation · 1998
- Coordinated multi-prong cancer therapy5US 11,207,392 B2Nant Holdings IP, LLC · 2021